Anti-angiogenic found in tears

Article

Pigment-epithelium-derived factor (PEDF), which is known for its importance in the prevention of neovascularization of the retina, can be found in measurable amounts in the human tear fluid of healthy subjects. It may therefore be important in the regulation of corneal vascularization.

Pigment-epithelium-derived factor (PEDF), which is known for its importance in the prevention of neovascularization of the retina, can be found in measurable amounts in the human tear fluid of healthy subjects. It may therefore be important in the regulation of corneal vascularization, according to a report published online ahead of print by Ophthalmic Research.

Oran Abdiu, MD and co-workers from St Erik's Eye Hospital, Karolinska Institutet, Stockholm, Sweden collected tear fluid samples from 18 healthy individuals and analysed them using a commercial ELISA. Samples were also collected from five patients with pterygium and, as a positive control, two samples were taken from the subretinal fluid of patients following retinal detachment surgery.

The researchers found that PEDF concentrations were below the detection limit (i.e. <0.1 ng/ml) in the majority of samples from healthy subjects. However, PEDF was discovered in three of the samples with significant concentrations of 2, 32 and 53 ng/ml. There were no detectable concentrations among the group with pterygium.

The researchers were therefore able to confirm that PEDF can be found in measurable amounts in human tear fluid of healthy individuals and it may play a role in the effects and regulation of vascularization at the ocular surface.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.